Iovance Phase 2 IOV-LUN-202 24.6% ORR in previously treated non-squamous metastatic NSCLC
Iovance reports Phase 2 IOV-LUN-202 data in mNSCLC and plans POSITILITY precision TIL cohort enrollment in November 2026
- Phase 2 IOV-LUN-202 showed 24.6% ORR in previously treated non-squamous metastatic NSCLC patients.
- Biomarker-enriched KRAS/HER2/smoking subgroup achieved 59.1% overall response rate in the Phase 2 IOV-LUN-202 trial.
- POSITILITY precision TIL cohort has registrational intent with enrollment planned to start in November 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.